Correspondence 0000950170-22-025776 from Virax Biolabs Group Ltd (VRAX) (CIK 0001885827) (VRAX)
Virax Biolabs Group Ltd (VRAX) (CIK 0001885827)
Date: Nov. 29, 2022 · CIK: 0001885827 · Accession: 0000950170-22-025776
AI Filing Summary & Sentiment
File numbers found in text: 333-268486
Letter
Virax Biolabs Group Limited
30 Broadwick Street
London, W1F 8LX
United Kingdom
VIA EDGAR
November 29, 2022
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn: Ada D. Sarmento
Re:
Virax Biolabs Group Limited
Registration Statement on Form F-1
Filed November 21, 2022
File No. 333-268486
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 1, 2022, or as soon as thereafter practicable.
Very truly yours,
/s/ James Foster
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Virax Biolabs Group Limited
30 Broadwick Street
London, W1F 8LX
United Kingdom
VIA EDGAR
November 29, 2022
U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn: Ada D. Sarmento
Re:
Virax Biolabs Group Limited
Registration Statement on Form F-1
Filed November 21, 2022
File No. 333-268486
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 1, 2022, or as soon as thereafter practicable.
Very truly yours,
/s/ James Foster
James Foster
Chief Executive Officer
DOCPROPERTY "DocID" \* MERGEFORMAT 23223630.1
240437-10002